诺和龙治疗2型糖尿病合并动脉粥样硬化患者的临床疗效分析  

Analysis of Clinical Efficacy of Nuo Helong Therapy in Patients with Type 2 Diabetes Mellitus with Atherosclerosis

作　　者：李春慧[1] 

机构地区：[1]辽宁省沈阳医学院附属中心医院,辽宁沈阳110024

出　　处：《中国医药指南》2014年第17期5-6,共2页Guide of China Medicine

摘　　要：目的对诺和龙治疗2型糖尿病合并动脉粥样硬化患者的临床疗效进行分析。方法按照双盲随机对照实验原则设计本研究方法,将112例2型糖尿病患者分为2组,即观察组和对照组,每组各56例,2组患者均给予常规口服降糖药物或皮下注射胰岛素治疗,观察组患者在此基础上加用诺和龙治疗,比较两组患者的治疗效果。结果观察组患者治疗后的FBG、2hPG、HbA1c、IL-6以及内膜中层厚度较对照组患者有显著改善,组间差异有统计学意义(P<0.05)。结论采用诺和龙治疗2型糖尿病合并动脉粥样硬化临床疗效可靠,值得进一步推广使用。ObjectiveThe clinical curative effect of treatment of patients with type 2 diabetes and atherosclerosis of repaglinide were analyzed. MethodsAccording to the randomized double blind study, 112 cases of type 2diabetic patients were divided into 2 groups, the observation group and the control group, 56 cases in each group, 2 groups of patients were givenconventional oral hypoglycemic agents or subcutaneous injection of insulin therapy, the patients in the observation group were treated in addition withrepaglinide, therapeutic effect of two groups were compared.ResultsThe observation group after treatment FBG, 2hPG, HbA1c, IL-6 and intima-media thickness than that of the control group patients were significantly improved, the differences between groups were statistically signiifcant （P〈0.05）.ConclusionTheclinical therapeutic effect of repaglinide in type 2 diabetic patients with atherosclerosis and reliable, worthy of further promotion.

关 键 词：2型糖尿病 诺和龙 动脉粥样硬化 临床疗效 

分 类 号：R587.1[医药卫生—内分泌] R541.4[医药卫生—内科学]